Morgan Stanley assumed coverage of BioAge Labs (BIOA) with an Underweight rating and $5 price target following the recent pipeline setback resulting in the discontinuation of lead program azeleprag. While the firm believes the pipeline may have potential, development remains in the early stages and Morgan Stanley awaits greater clarity.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BIOA:
- Cautious Outlook on BioAge Labs, Inc. Amid Program Discontinuation and Development Risks
- BioAge Labs initiated with a Market Perform at William Blair
- Hold Rating for BioAge Labs, Inc.: Balancing Innovative Potential with Competitive and Developmental Challenges
- BIOA Lawsuit Alert! Class Action Lawsuit Against BioAge Labs, Inc.
- Nine new option listings on February 12th